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Abstract: Age-related increases in intermuscular adipose tissue (IMAT) impair muscle quality,
decrease functional capacity, and promote several cardiometabolic and inflammatory disorders.
Whether these age-related alterations in muscle composition improve by consuming a high-protein
(HP) diet with whole eggs are unclear. This parallel-design, randomized-controlled trial assessed
the effects of a 12-week eucaloric HP diet with three whole eggs per day (1.4 g protein kg−1 day−1)
versus a normal-protein diet void of eggs (NP, 0.8 g protein kg−1 day−1) on muscle composition
(IMAT), cardiometabolic health, and systemic inflammation in older adults with overweight or obesity
(12 men and 10 women; age 70 ± 5 years, BMI 31.3 ± 3.2 kg/m2, mean ± SD). No changes in muscle
composition were observed over time, independent of protein intake. Total body weight was reduced
in both groups (−3.3 ± 1.2%) and lean mass was preserved only with the HP diet. LDL concentration
and hip circumference decreased only with the NP diet, while MCP-1 and HsCRP concentrations
increased over time in both groups. A HP diet with whole eggs promotes lean mass retention with
modest weight loss, but does not positively influence muscle composition, cardiometabolic health or
systemic inflammation, compared to a NP diet void of eggs.
Keywords: dietary protein; eggs; diet composition; skeletal muscle composition; intermuscular
adipose tissue; inflammation
1. Introduction
Ectopic adipose tissue accumulation is an important hallmark of metabolic dysfunction and
chronic disease. Obesity is strongly associated with metabolic and inflammatory disorders and
recent evidence supports the anatomical location of adipose tissue [1–5] and its metabolic type [6]
as determinants of the development of obesity-related disorders [7–10]. While gynoid adiposity
(accumulation of adipose tissue in the thigh area) may be cardio-protective [10,11], adipose tissue
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located at ectopic sites like skeletal muscle, liver, or the intra-abdominal cavity are strongly associated
with chronic inflammation [7,12], impaired glucose tolerance [1–3,13] and hyperlipidemia [5,14].
In particular, intermuscular adipose tissue (IMAT), adipose tissue located beneath the fascia
and between muscle fibers and groups, impairs muscle quality and reduces insulin-stimulated
skeletal muscle glucose uptake [15,16]. As such, increased IMAT is associated with insulin
resistance [2,3,5,10,17], systemic inflammation [18,19], and skeletal muscle dysfunction, which is
characterized by decreased muscle strength [20–24], function [25–27], and mobility [22,26–28].
Exercise and/or energy restriction are currently the two primary strategies for decreasing IMAT,
with the greatest improvements in muscle composition occurring with a ≥10% decrease in body
weight [29–33]. However, the effect of diet composition on IMAT concentrations in the absence of
weight loss or with only modest weight loss has received little attention. This is of particular importance
for older adults, a population prone to IMAT accumulation, where excessive weight loss may further
impair muscle health and increase the symptoms of sarcopenia [34]. One potentially effective dietary
strategy for decreasing IMAT in older adults is increasing total protein intake. Higher protein intakes
are associated with improvements in body composition [35,36], glucose tolerance [37], inflammatory
status [38,39], and postprandial lipemia [40,41].
Eggs are a nutrient dense whole-food source of dietary protein and antioxidants. Egg protein is
highly bioavailable and able to effectively stimulate muscle protein synthesis [42]. Eggs are also a rich
source of lutein and zeaxanthin [39]. Consuming 3 whole eggs per day for 12 weeks increased plasma
concentrations of these carotenoids and adiponectin, which reduced systemic inflammation [39].
Adiponectin promotes the reduction of catabolic inflammatory cytokines and is inversely correlated
with muscle fat storage [43–45]. A high-protein diet containing whole eggs may therefore reduce IMAT
by decreasing overall adiposity, circulating postprandial fatty acids and inflammatory cytokines, and
skeletal muscle lipid uptake [39,43].
The objective of this randomized controlled trial was to assess the effects of a high-protein diet
with whole eggs, versus a normal protein diet void of eggs on muscle composition in older adults
with overweight or obesity; with secondary endpoints including clinical indexes of cardiometabolic
health and systemic inflammation. It was hypothesized that consumption of a high-protein diet with
whole eggs for 12 weeks would improve muscle composition, cardiometabolic status, and systemic
inflammation markers compared to consuming a normal protein diet void of eggs.
2. Materials and Methods
2.1. Participant Characteristics and Design
Twenty-two adults were randomized to consume either a high-protein diet (HP) or a normal
protein diet (NP) for 12 weeks (Figure 1). The inclusion criteria were as follows: male and female,
age 50–80 years old; BMI 25–38 kg/m2; weight stable (±3 kg) during last 3 months; not currently or
within the past 3 months following an exercise or weight loss program; non-diabetic; fasting glucose
<110 mg/dL; blood pressure <160/100 mmHg; plasma total cholesterol <260 mg/dL; LDL-cholesterol
<160 mg/dL; triacylglycerol <400 mg/dL; markers of kidney, liver, and heart functions within 10%
of clinical normalcy. Participants habitually (≥3 months) consuming one or more medications for
hypothyroidism (HP = 1, NP = 2), high blood pressure (HP = 6, NP = 3), and/or high cholesterol
(HP = 4, NP = 2) were not excluded from the study. The study complied with the Declaration of
Helsinki as revised in 2013 and the protocol received approval from the Biomedical Institutional Review
Board at Purdue University. Each participant signed an informed consent document and received a
monetary stipend for participation. The study is registered at clinicaltrials.gov as NCT01396915.
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Figure 1. Consolidated Standards of Reporting Trials flow diagram. Flow of participants and study 
analysis. Females, F; High protein, HP; Males, M; Normal protein, NP. 
2.2. Dietary Intervention 
Participants were randomly assigned (Microsoft Excel 2010, randomization function), to 1 of 2 
dietary interventions: (1) a HP diet (n = 12) with 1.4 g protein kg−1 day−1; ~27% of energy from protein, 
43% carbohydrate and 30% from fat, or (2) a NP diet (n = 10) with 0.8 g protein kg−1 day−1; ~15% of 
energy from protein, 55% carbohydrate and 30% from fat. The HP diet included ~50 g/day of 
additional dietary protein in comparison to the NP diet over the course of breakfast, lunch and mid-
afternoon snack meals. The majority (59%) of the additional dietary protein came from whole eggs (3 
eggs/day) and other egg products. Additional protein also came from higher dairy (26%), meat (20%), 
and plant (2%) sources, along with modestly reduced protein intakes from grains (−1%) and 
miscellaneous (−6%) sources. Participants consuming the HP diet were provided and asked to 
completely consume 3 whole eggs at breakfast, providing 20 g of dietary protein, and an egg-based 
afternoon snack, providing an additional ~10 g of dietary protein. Participants consuming the NP diet 
were restricted from eating eggs and egg products throughout the intervention but were provided 
and consumed isocaloric non-egg items at breakfast and as an afternoon snack. Each participant was 
provided and required to follow a rotating biweekly menu specific to their dietary group and daily 
energy requirement was estimated using sex-specific equations from the Institute of Medicine [46] 
for adults with overweight and obesity for the purpose of maintaining body weight. Within-day 
dietary protein intake was ≥20 g at four eating occasions for the HP diet compared to one eating 
occasion per day in the NP diet. An example of the daily protein intake and protein source 
distribution of each meal for a representative 85 kg participant averaged over a week for each diet is 
presented in Table 1. 
Figure 1. Consolidated Standards of Reporting Trials flow diagram. Flow of participants and
study analysis. Females, F; High protein, HP; Males, M; Normal protein, NP.
2.2. Dietary Intervention
Participants were randomly assigned (Microsoft Excel 2010, randomization function), to 1 of
2 dietary interventio s: (1) a HP diet (n = 12) with 1.4 g protein kg−1 day−1; ~27% of energy from
protein, 43% carb hydrate and 30% from f t, or (2) a NP diet (n = 10) with 0.8 g protein k −1 day−1;
~15% of e ergy from protein, 55% carb hydrate an 30% f om fat. The HP diet incl ded ~50 g/day
of dditi al dietary protein in comparison to the NP diet ove the course of breakfast, lunch and
mid-afternoo snack meals. The majority (59%) of the additional dietary protein came from whole
eggs (3 eggs/day) and other egg products. Additional protein also came from higher dairy (26%),
meat (20%), and plant (2%) sources, along with modestly reduced protein intakes from grains (−1%)
and miscellaneous (−6%) sources. Participants consuming the HP diet were provided and asked to
completely consume 3 whole eggs at breakfast, providing 20 g of dietary protein, and an egg-based
afternoon snack, providing an additional ~10 g of dietary protein. Participants consuming the NP diet
were restricted from eating eggs and egg products throughout the intervention but were provided
and consumed isocaloric non-egg items at breakfast and as an afternoon snack. Each participant was
provided and required to follow a rotating biweekly menu specific to their dietary group and daily
energy requirement was estimated using sex-specific equations from the Institute of Medicine [46] for
adults with overweight and obesity for the purpose of maintaining body weight. Within-day dietary
protein intake was ≥20 g at four eating occasions for the HP diet compared to one eating occasion per
day in the NP diet. An example of the daily protein intake and protein source distribution of each
meal for a representative 85 kg participant averaged over a week for each diet is presented in Table 1.
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Table 1. Average daily protein intake and source distribution for a representative 85 kg adult
participant 1.
Total Egg Meat Plant Grain Dairy Residual
NP
Breakfast, g 12.7 0.0 3.0 0.6 7.0 1.1 0.9
Lunch, g 12.6 0.0 2.7 0.6 4.5 2.8 1.9
Dinner, g 31.7 0.0 15.0 1.6 6.5 6.2 2.4
Snack, g 12.5 0.0 0.0 3.5 0.0 7.7 1.3
Total Intake, g 69.5 0.0 20.7 6.3 18.1 17.8 6.5
Percentage, % 100% 0% 30% 9% 26% 26% 9%
HP
Breakfast, g 30.0 12.5 6.2 1.3 7.6 1.8 0.6
Lunch, g 31.2 6.3 8.1 2.3 5.6 8.6 0.3
Dinner, g 32.4 0.0 16.2 1.5 4.6 7.9 2.2
Snack, g 25.8 10.6 0.0 2.2 0.0 12.5 0.5
Total Intake, g 119.4 29.4 30.5 7.4 17.8 30.8 3.5
Percentage, % 100% 25% 26% 6% 15% 26% 3%
Added Protein (HP-NP)
Breakfast, g 17.3 12.5 3.2 0.7 0.6 0.7 −0.3
Lunch, g 18.6 6.3 5.4 1.7 1.1 5.8 −1.6
Dinner, g 0.7 0.0 1.2 −0.1 −1.9 1.7 −0.2
Snack, g 13.3 10.6 0.0 −1.3 0.0 4.8 −0.8
Total Intake, g 49.9 29.4 9.8 1.1 −0.3 13.0 −3.0
Percentage, % 100% 59% 20% 2% −1% 26% −6%
1 HP, High protein; NP, Normal protein.
Three 24-hour dietary recalls were collected on two weekdays (in-person) and one weekend day
(phone interview) by either a registered dietitian or trained clinical research technician to assess the
participants’ usual dietary intake before the start of the study. Participants completed daily menu
checklists to document adherence to the diet during the 12-week intervention. Checklists were checked
on a weekly basis by a registered dietitian or trained clinical research technician following food pick-up.
Blood urea nitrogen (BUN) was assessed during the study as a crude marker of protein intake and
dietary compliance at study weeks 0 (baseline), 4, 8, and 12. To promote body weight maintenance
throughout the 12-week intervention, adjustments to the participant’s non-protein energy intakes were
made if baseline body weight changed by >2 kg.
2.3. Muscle Composition
Medial muscle cross-sectional areas (MCSA), muscle volumes and IMATs of the thigh and calf
were accessed by Magnetic Resonance Imaging (MRI). IMAT includes inter-muscular adipose tissue
that resides between muscle groups and under the muscle fascia as well as intra-muscular adipose
tissue that is located within muscles [47]. MRI’s of the thigh and calf muscles were obtained using a
3T General Electric (Waukesha, WI, USA) Signa HDx system at the Purdue MRI Facility. Following a
1-hour supine rest period to control for posture-related fluid shifts in muscle [48], participants were
asked to lie with their heels in a fixed position on a nonmetallic support to control both the joint and
scan angle while at the same time minimizing the compression of the legs. Following a localizer scan
to ascertain the initial imaging position of the legs, a fast gradient echo sequence (TR/TE = 660/6.1 ms;
FOV = 48 cm; acquisition matrix = 384 × 336; slice thickness = 6 mm; 60 axial slices) was performed.
Muscle and adipose tissue volumes and MCSA were visualized and quantified using the analysis
software MIPAV (Medical Image Processing, Analysis & Visualization, v. 7.0; Center for Information
Technology, National Institutes of Health, Bethesda, MD, USA). The IMAT located between and within
muscles was differentiated from subcutaneous adipose tissue by tracing the facial plane around the
thigh by a trained member of the research staff. A Shading Correction algorithm (Inhomogeneity
N3 correction) was applied followed by a Segmentation algorithm (Fuzzy Means, Single Channel) to
quantify IMAT and muscle volume of each slice. Beginning with the appearance of the rectus femoris
and ending with the appearance of the gluteus maximus, every third axial slice of the medial thigh
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was quantified in triplicate for MCSA, muscle volume and IMAT, which were then averaged and
summed to calculate total thigh volumes. A similar protocol was carried out in the quantification of
calf MCSA, muscle volume and IMAT, beginning with the appearance of the peroneus longus and
ending with the disappearance of the gastrocnemius. Due to involuntary movement, which impaired
tissue quantification, reduced sample sizes for medial thigh (HP (n = 9), NP (n = 8)) and medial calf
(HP (n = 8), NP (n = 7)) are included in these analyses.
2.4. Whole Body Composition
Fasting-state body mass (total mass-robe mass) was measured every week using a digital platform
scale (model ES200L, Ohaus Corporation, Pine Brook, NJ, USA) and standing height without shoes
was measured at baseline using a wall-mounted stadiometer. Body mass index was calculated as
(kg/m2) from these measurements. Waist circumference was measured in the standing position
at the narrowest position between the lateral lower rib and the iliac crest. Hip circumference was
measured in the standing position at the largest circumference of the lower abdomen. Waist and hip
measurements were performed in triplicate at baseline and post-intervention and the time-specific
mean values were recorded. Whole body and regional lean tissue and fat masses were also measured
at baseline and post-intervention using dual-energy X-ray absorptiometry (DXA; GE Lunar Prodigy
with version 11.1 enCORE iDXA software, Madison, WI, USA). Automatic daily calibrations of DXA
imaging were conducted throughout the study and weekly quality-assurance tests were conducted
utilizing a calibrated phantom spine.
2.5. Clinical Health Assessments
At baseline and post-intervention, blood samples were collected from an antecubital vein
following an overnight fast and placed in tubes containing a clot activator to obtain serum or sodium
heparin to obtain plasma (BD Vacutainer Brand; Becton, Dickinson and Co., Franklin Lakes, NJ,
USA). Serum samples were sent to Mid-American Clinical Labs (Indianapolis, IN, USA) for analysis
(comprehensive metabolic panel and lipid-lipoprotein panel). Plasma tubes were immediately placed
on ice for 30 mins and centrifuged at 4 ◦C for 15 min at 4400 rpm. Aliquots of plasma were stored in
microcentrifuge tubes at −80 ◦C for subsequent Cardiac High Sensitive C-reactive protein (HsCRP),
tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1),
insulin-like growth factor 1 (IGF-1) and adiponectin analyses. Blood pressure was measured in
duplicate in the supine and reclining position following a 15-minute resting period using an electronic
sphygmomanometer (Omron, Model # BP785; Kyoto, Japan) at baseline and the post-intervention.
2.6. Blood Analyses
Fasting plasma HsCRP was measured on a COBAS Integra 400 analyzer (Roche Diagnostic
Systems) with a within-run precision coefficient of variance (CV) of 1.3% and a functional sensitivity
(limit of quantitation) of 0.3 mg/L (2.96 nmol/L). Fasting plasma TNFα and IL-6 were determined
by sandwich enzyme-linked immunosorbent assay (ELISA, Cayman Chemical Company, Ann Arbor,
MI, USA) according to the manufacturer’s instructions with the following assay parameters: TNFα,
intra-assay CV (5.7–9.2%), inter-assay CV (9.8–10.4%), detection limit (3.9 pg/mL); IL-6, intra-assay CV
(4.1–5.1%), inter-assay CV (5.4–7.3%), detection limit (7.8 pg/mL). Fasting plasma MCP-1, IGF-1 and
adiponectin were determined by sandwich ELISA (Sigma-Aldrich, St. Louis, MO, USA) according
to the manufacturer’s instructions with an intra-assay and inter-assay CV of <10% and <12% and
detection limits of <2 pg/mL, <2 ng/mL, and <25 pg/mL, respectively. All samples were measured in
duplicate and absorbance was measured at 405 nm (TNFα, IL-6) or 450 nm (MCP-1, IGF-1, adiponectin)
on an absorbance microplate reader (BioTeck EL × 808, Winooski, VT, USA).
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2.7. Sample Size Estimation
At the time of study conception, we were unable to find a suitable study, one without an exercise
or weight loss component, from which to derive statistical power calculations for our primary outcome
of interest (IMAT). The Schrauwen-Hinderling et al. study revealed that intramyocellular lipid (IMCL)
content increased following a 1-week high fat vs low fat diet (9.40 ± 1.87 vs. 6.12 ± 0.94 mmol/kg
muscle wet weight, effect size = 2.2), demonstrating that diet can induce changes in skeletal muscle
fat storage [49]. Due to considerable differences in study designs and indices of skeletal muscle
composition (IMAT vs. IMCL), the current study was powered (80% power, α = 0.05) to detect a
difference in IMAT concentration between diets that is equal to one standard deviation of the change
(effect size = 1.0). Power calculations were also derived for changes in serum triglyceride concentrations
as a secondary outcome of interest. Based upon a 16-week amino acid supplementation trial in older
adults [50], 9 participants per group are needed to confirm a differential response of 0.30 mmol/L with
>90% power (two-tailed, p < 0.05).
2.8. Statistical Analysis
Data distributions were reviewed and outliers were excluded according to the outlier labeling
rule [51]. Baseline and post-intervention differences between groups were assessed using independent
t-tests. Biological sex was established to be a significant covariant for multiple outcomes of interest.
Effect of time, independent of diet and sex, on cardiometabolic outcomes was determined by
paired t-test. Repeated-measures ANCOVA, controlling for sex, were performed to determine the main
effects of diet, time, and diet-by-time interactions on muscle composition, cardiometabolic health, and
systemic inflammation parameters. Significant diet-by-time interactions were followed up in post-hoc
analyses through the comparison of simple main effects using Bonferroni correction. Significance
was denoted with a corrected p value < 0.05. All statistical analyses were performed using SPSS
statistical software (version 21; IBM Corporation 2012, Armonk, NY, USA). Results are presented as
mean ± standard deviation.
3. Results
3.1. Participant Characteristics
Baseline participant characteristics are presented in Table 2. No differences in muscle and
body compositions, anthropometrics, serum markers of fasting glucose, insulin, blood lipids, or
macronutrient composition were observed between the HP and NP groups at baseline. Collectively,
daily menu checklists indicated a compliance of 91% to the dietary intervention. BUN concentrations
increased over time (p = 0.035) and were higher post-intervention with the HP diet versus the NP
diet (p = 0.013). The BUN results provide a crude objective assessment of dietary protein intakes.
Apparently, there were no differences in protein intakes of NP vs. HP at baseline, and no change in
protein intake over time for NP. In contrast, protein intake increased over time for HP, and was higher
for HP vs. NP at post-intervention.
Table 2. Baseline participant characteristics 1.
Variable All HP NP
n 22 12 10
Age, years 70 ± 5 70 ± 6 71 ± 3
Male:Female 12:10 7:5 5:5
Body mass, kg 92.1 ± 15.4 90.1 ± 16.4 91.0 ± 16.1
Height, cm 171 ± 11 167 ± 12 172 ± 9
BMI, kg/m 2 31.3 ± 3.2 32.2 ± 3.4 30.5 ± 3.3
Waist, cm 110 ± 9 110 ± 11 110 ± 9
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Variable All HP NP
Hip, cm 115 ± 9 114 ± 11 115 ± 9
Lean mass, kg 51.3 ± 10.9 49.0 ± 11.6 50.7 ± 10.3
Fat mass, kg 37.2 ± 8.4 37.6 ± 9.2 36.9 ± 8.9
Percentage body fat 42.1 ± 7.3 43.5 ± 8.3 42.0 ± 6.7
Fasting glucose, mg/dL 99.2 ± 9.7 98.1 ± 11.1 98.3 ± 10.0
Fasting insulin, µU/mL 13.1 ± 7.5 11.4 ± 7.1 13.1 ± 7.2
HOMA-IR 3.3 ± 2.1 2.8 ± 2.1 3.3 ± 2.0
Total cholesterol, mg/dL 190.4 ± 37.0 201.4 ± 33.5 185.5 ± 26.7
LDL cholesterol, mg/dL 115.7 ± 32.4 123.5 ± 38.0 111.5 ± 18.2
HDL cholesterol, mg/dL 48.7 ± 14.6 54.0 ± 11.2 47.6 ± 18.1
Total Cholesterol:HDL 4.2 ± 1.2 3.9 ± 1.1 4.3 ± 1.5
Triglycerides, mg/dL 130.1 ± 58.6 119.9 ± 64.0 131.6 ± 64.7
Manual SBP 3, mm Hg 132 ± 14 129 ± 12 134 ± 15
Manual DBP 3, mm Hg 84 ± 7 81 ± 7 86 ± 8
BUN, mg/dL 16.5 ± 3.3 17.0 ± 4.6 16.2 ± 2.6
Total Energy, kcal/day 2011 ± 537 2061 ± 597 1957 ± 597
Total Fat, g/day 79 ± 31 82 ± 35 75 ± 35
Total Fat, % 34 ± 7 34 ± 6 33 ± 6
Total Carbohydrates, g/day 245 ± 69 249 ± 71 241 ± 71
Total Carbohydrates, % 48 ± 8 48 ± 6 48 ± 6
Total Protein, g/day 82 ± 24 84 ± 15 79 ± 15
Total Protein, % 17 ± 5 16 ± 4 17 ± 4
Animal Protein, g/day 54 ± 25 55 ± 12 53 ± 12
Vegetable Protein, g/day 28 ± 8 29 ± 6 27 ± 6
1 Mean ± SD; 2 BUN, Blood urea nitrogen; DBP, Diastolic blood pressure; HDL, High-density lipoprotein; HP, High
protein; HOMA-IR, Homeostatic model assessment of insulin resistance; LDL, Low-density lipoprotein; NP, Normal
protein; SBP, Systolic blood pressure. 3 Medication usage: hypothyroidism (HP = 1, NP = 2), high blood pressure
(HP = 6, NP = 3), and/or high cholesterol (HP = 4, NP = 2).
3.2. Muscle Composition
MRI measurements of mid-thigh or mid-calf muscle composition were largely unaffected over
the 12-week intervention or between dietary groups (Table 3). Subcutaneous fat to muscle volume
ratio, however, decreased over time at the mid-calf with HP diet but not the NP diet (p = 0.031).
Table 3. MRI-derived measurements of muscle composition 1.
Baseline Post ∆
Thigh (n = 18) (n = 19) (n = 18)
MCSA, mm2 × 104 NP 258.4 ± 54.0 218.9 ± 47.0 −29.2 ± 65.1
HP 260.2 ± 69.4 254.4 ± 98.50 9.3 ± 114.0
All 259.3 ± 60.3 237.6 ± 78.5 −8.8 ± 93.5
SubQ, mm2 × 104 NP 104.8 ± 49.0 68.3 ± 36.4 −28.6 ± 33.8
HP 82.1 ± 42.0 82.4 ± 35.9 1.8 ± 53.8
All 93.5 ± 45.7 75.7 ± 45.7 −12.5 ± 46.8
IMAT, mm3 × 104 NP 16.7 ± 11.3 12.5 ± 4.4 −4.9 ± 10.2
HP 17.9 ± 7.8 15.1 ± 7.4 −2.0 ± 6.1
All 17.3 ± 9.4 13.9 ± 6.1 −3.3 ± 8.2
Muscle Volume, mm3 × 104 NP 119.5 ± 38.7 110.5 ± 45.3 −7.4 ± 28.3
HP 151.4 ± 68.2 125.5 ± 61.1 −16.2 ± 60.5
All 135.4 ± 56.3 118.4 ± 53.2 −12.1 ± 46.9
Total Fat:CSA NP 0.47 ± 0.16 0.38 ± 0.16 −0.07 ± 0.06
HP 0.40 ± 0.18 0.40 ± 0.15 −0.02 ± 0.10
All 0.43 ± 0.17 0.39 ± 0.15 −0.04 ± 0.09
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Table 3. Cont.
Baseline Post ∆
IMAT:Muscle Volume NP 0.12 ± 0.04 0.12 ± 0.03 −0.03 ± 0.06
HP 0.11 ± 0.03 0.13 ± 0.05 −0.01 ± 0.01
All 0.12 ± 0.03 0.13 ± 0.04 −0.02 ± 0.04
SubQ:Muscle Volume NP 1.03 ± 0.64 0.82 ± 0.72 −0.10 ± 0.28
HP 0.78 ± 0.73 0.87 ± 0.64 −0.01 ± 0.31
All 0.90 ± 0.68 0.85 ± 0.66 −0.05 ± 0.29
Calf (n = 15) (n = 17) (n = 15)
MCSA, mm2 × 104 NP 134.9 ± 28.8 143.6 ± 41.6 2.0 ± 15.5
HP 142.0 ± 30.7 141.0 ± 27.2 −1.9 ± 4.8
All 138.6 ± 29.0 142.2 ± 33.6 0.2 ± 11.6
SubQ, mm2 × 104 NP 48.3 ± 41.6 49.8 ± 25.2 0.6 ± 2.7
HP 48.8 ± 33.7 49.8 ± 31.9 −0.9 ± 2.0
All 48.6 ± 30.3 49.8 ± 28.0 −0.1 ± 2.4
IMAT, mm3 × 104 NP 9.3 ± 3.3 9.9 ± 4.6 −0.6 ± 1.3
HP 10.0 ± 3.6 10.0 ± 3.6 −1.1 ± 1.0
All 9.7 ± 3.4 9.9 ± 3.3 −0.9 ± 1.1
Muscle Volume, mm3 × 104 NP 77.6 ± 21.7 80.5 ± 22.3 1.2 ± 6.9
HP 79.6 ± 18.3 79.2 ± 18.3 −0.5 ± 3.0
All 78.6 ± 19.3 79.8 ± 20.1 −0.2 ± 5.3
Total Fat: CSA NP 0.44 ± 0.23 0.44 ± 0.22 0.01 ± 0.06
HP 0.42 ± 0.25 0.43 ± 0.24 −0.01 ± 0.01
All 0.43 ± 0.23 0.43 ± 0.22 −0.004 ± 0.05
IMAT:Muscle Volume NP 0.12 ± 0.04 0.12 ± 0.05 −0.01 ± 0.02
HP 0.12 ± 0.03 0.13 ± 0.03 −0.01 ± 0.01
All 0.12 ± 0.03 0.13 ± 0.04 −0.01 ± 0.01
SubQ:Muscle Volume NP 0.67 ± 0.39 0.66± 0.36 0.01 ± 0.02 A
HP 0.64 ± 0.43 0.68 ± 0.44 −0.01 ± 0.02A,B
All 0.66 ± 0.40 0.67 ± 0.40 −0.002 ± 0.02
1 Mean ± SD; Repeated measures ANOVA controlling for sex: Diet-by-Time Interaction (A p values < 0.05), Time
Effect (B p values < 0.05). HP, High protein; NP, Normal protein; MAT, Intramuscular adipose tissue; MCSA, Muscle
cross-sectional area; MRI, Magnetic resonance imaging; SubQ, Subcutaneous fat.
3.3. Whole Body Composition
Body weight (−3.00± 2.43 kg, p = 0.022, partial r2 = 0.246; Figure 2) and body fat (−2.25± 1.67 kg,
p = 0.011, partial r2 = 0.266; Table 4) were reduced in both HP and NP diet groups over the 12-week
dietary intervention. Changes in total lean mass (group × time, p = 0.05, partial r2 = 0.182), trunk
lean mass (group × time, p = 0.015, partial r2 = 0.274), and appendicular fat mass (group × time,
p = 0.033, partial r2 = 0.219) over time differed between the two diets. The HP diet prevented changes
in lean mass (trunk lean mass (p = 0.568); total lean mass (p = 0.391)), while the NP diet decreased lean
mass over the 12-week intervention (trunk lean mass (p = 0.006); total lean mass (p = 0.002); Table 4).
Though both diets decreased appendicular fat mass over time, greater decreases were observed with
the NP diet in comparison to the HP diet (p = 0.033, partial r2 = 0.219; Table 4).
Table 4. Body composition 1.
Baseline Post ∆
(n = 22) (n = 22) (n = 22)
Appendicular fat mass, kg NP 15.72 ± 4.23 14.68 ± 4.05 −1.04 ± 0.76 A
HP 14.84 ± 4.99 14.41 ± 4.94 −0.43 ± 0.52 A
All 15.24 ± 4.58 14.53 ± 4.45 −0.71 ± 0.70
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Table 4. Cont.
Baseline Post ∆
(n = 22) (n = 22) (n = 22)
Appendicular lean mass, kg NP 23.34 ± 5.49 22.76 ± 5.56 −0.58 ± 0.66
HP 23.61 ± 5.93 23.22 ± 5.90 −0.39 ± 0.71
All 23.49 ± 5.60 23.01 ± 5.62 −0.48 ± 0.68
Trunk fat mass, kg NP 20.13 ± 6.27 18.51 ± 6.32 −1.62 ± 1.21
HP 21.64 ± 4.89 20.18 ± 5.05 −1.46 ± 1.16
All 20.95 ± 5.47 19.42 ± 5.59 −1.53 ± 1.16
Trunk lean mass, kg NP 23.98 ± 4.67 23.30 ± 4.58 −0.68 ± 0.72 A
HP 24.69 ± 5.49 24.81 ± 5.56 0.12 ± 0.63 A
All 24.37 ± 5.03 24.13 ± 5.08 −0.24 ± 0.77
Percent body fat NP 41.99 ± 6.65 40.75 ± 6.77 −1.24 ± 1.26
HP 42.20 ± 8.14 41.00 ± 8.26 −1.20 ± 1.04
All 42.11 ± 7.33 40.88 ± 7.44 −1.22 ± 1.11
Total fat mass, kg NP 36.83 ± 8.85 34.15 ± 8.98 −2.68 ± 1.81
HP 37.50 ± 8.32 35.60 ± 8.65 −1.90 ± 1.52
All 37.20 ± 8.37 34.94 ± 8.62 −2.25 ± 1.67 B
Total lean mass, kg NP 50.71 ± 10.33 49.42 ± 10.37 −1.29 ± 0.97 A,B
HP 51.80 ± 11.77 51.52 ± 11.76 −0.28 ± 1.20 A
All 51.30 ± 10.89 50.56 ± 10.94 −0.74 ± 1.19
Total mass, kg NP 90.5 ± 15.8 86.49 ± 16.23 −3.96 ± 2.12
HP 92.1 ± 15.4 89.89 ± 16.07 −2.20 ± 2.46
All 91.3 ± 15.2 88.3 ± 15.8 −3.00 ± 2.43 B
1 Mean ± SD; Repeated measures ANCOVA controlling for sex: Diet-by-Time Interaction (A p values < 0.05), Time
Effect (B p values < 0.05). HP, High protein; NP, Normal protein.
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Figure 2. Changes in body weight over 12-week dietary intervention between the high protein and
normal protein diet. Mean ± SD; Repeated measures ANCOVA controlling for sex: Time Effect
(# p values < 0.05). High protein, HP; Normal protein, NP.
3.4. Indices of Cardiometabolic Health
Independent of diet, IGF-1 concentrations increased over time (p = 0.042, partial r2 = 0.262) with a
trend for an increase in the HP diet but no change in the NP diet (p = 0.082; Table 5). LDL concentration
(p = 0.015, partial r2 = 0.274) and hip circumference (p = 0.003, partial r2 = 0.450) decreased over time
Nutrients 2018, 10, 946 10 of 17
with the NP diet but were not different from baseline with the HP diet (Table 5). Diet did not influence
fasting glucose and insulin concentrations or other markers of cardiometabolic health (Table 5).
Table 5. Indices of cardiometabolic health 1.
Baseline Post ∆
(n = 22) (n = 22) (n = 22)
Waist, cm NP 110 ± 9 102 ± 13 −8 ± 9
HP 110 ± 11 107 ± 13 −3 ± 8
All 110 ± 9 105 ± 13 −5 ± 9 B
(n = 22) (n = 22) (n = 22)
Hip, cm NP 115 ± 9 111 ± 12 −5 ± 3 A,B
HP 114 ± 11 116 ± 9 1 ± 4 A
All 115 ± 9 114 ± 10 −2 ± 5
(n = 22) (n = 22) (n = 22)
Fasting glucose, mmol/L NP 5.5 ± 0.6 5.5 ± 0.4 0.0 ± 0.6
HP 5.6 ± 0.5 5.4 ± 0.5 −0.1 ± 0.4
All 5.5 ± 0.5 5.5 ± 0.5 −0.1 ± 0.5
(n = 19) (n = 22) (n = 19)
Fasting insulin, mmol/L NP 91.0 ± 50.0 82.6 ± 36.1 −8.3 ± 38.9
HP 90.3 ± 57.6 62.5 ± 37.5 −35.4 ± 34.7
All 91 ± 52.1 69.5 ± 36.8 −21.5 ± 38.2
HOMA-IR NP 3.26 ± 1.98 2.92 ± 1.33 −0.35 ± 1.59
HP 3.32 ± 2.43 2.23 ± 1.43 −1.37 ± 1.51
All 3.29 ± 2.15 2.55 ± 1.40 −0.83 ± 1.60
(n = 22) (n = 22) (n = 22)
Total cholesterol, mmol/L NP 4.8 ± 0.7 4.6 ± 0.8 −0.2 ± 0.4
HP 5.0 ± 1.2 5.0 ± 1.1 <−0.1 ± 0.6
All 4.9 ± 1.0 4.8 ± 1.0 −0.1 ± 0.5
LDL cholesterol, mmol/L NP 2.9 ± 0.5 2.6 ± 0.5 −0.3 ± 0.3 A,B
HP 3.1 ± 1.1 3.2 ± 1.0 0.1 ± 0.4 A
All 3.0 ± 0.8 3.0 ± 0.9 <−0.1 ± 0.4
HDL cholesterol, mmol/L NP 1.2 ± 0.5 1.2 ± 0.5 <−0.1 ± 0.2
HP 1.3 ± 0.3 1.2 ± 0.3 −0.1 ± 0.2
All 1.3 ± 0.4 1.2 ± 0.4 −0.1 ± 0.2
Cholesterol: HDL NP 4.33 ± 1.50 4.12 ± 1.27 −0.21 ± 0.56
HP 4.04 ± 1.02 4.18 ± 0.95 0.14 ± 0.36
All 4.17 ± 1.24 4.15 ± 1.08 −0.02 ± 0.48
Triglycerides, mmol/L NP 1.5 ± 0.7 1.6 ± 0.8 0.1 ± 0.4
HP 1.5 ± 0.6 1.2 ± 0.4 −0.3 ± 0.6
All 1.5 ± 0.7 1.4 ± 0.6 −0.1 ± 0.5
Manual SBP 3, mm HG NP 134 ± 15 132 ± 11 −2 ± 12
HP 130 ± 14 123 ± 17 −7 ± 13
All 132 ± 14 127 ± 14 −4 ± 13
Manual DBP 3, mm HG NP 86 ± 8 84 ± 7 −2 ± 6
HP 83 ± 6 78 ± 10 −5 ± 5
All 84 ± 7 81 ± 9 −4 ± 6
BUN 2, mmol/L NP 5.8 ± 0.9 5.6 ± 1.2 C −0.2 ± 1.2 A
HP 6.0 ± 1.4 7.6 ± 2.6 C 1.6 ± 1.8 A,B
All 5.9 ± 1.2 6.7 ± 2.2 0.8 ± 1.8
(n = 17) (n = 17) (n = 17)
IGF-1, pg/ml NP 1.52 ± 0.99 1.37 ± 0.69 −0.15 ± 0.43
HP 1.95 ± 1.71 2.82 ± 2.47 0.99 ± 1.81
All 1.80 ± 1.47 2.31 ± 2.11 0.56 ± 1.53 B
1 Mean ± SD; Repeated measures ANOVA controlling for sex: Diet-by-Time Interaction (A p values < 0.05), Time
Effect (B p values < 0.05); Post Independent t-Test (C p values < 0.05). 2 BUN, Blood urea nitrogen; DBP, Diastolic
blood pressure; HDL, High-density lipoprotein; HP, High protein; HOMA-IR, Homeostatic model assessment of
insulin resistance; IGF-1, Insulin-like growth factor 1; LDL, Low-density lipoprotein; NP, Normal protein; SBP,
Systolic blood pressure. 3 Measured in the seated position.
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3.5. Systemic Inflammation
Diet did not influence plasma inflammatory markers (Table 6). Independent of diet, MCP-1
concentration (p = 0.028, partial r2 = 0.253) and HsCRP concentration (p = 0.011, partial r2 = 0.341)
increased over time.
Table 6. Inflammatory status 1.
Baseline Post ∆
(n = 21) (n = 20) (n = 20)
HsCRP, mg/L NP 2.25 ± 1.50 2.10 ± 1.77 −0.14 ± 0.97
HP 1.32 ± 1.08 1.62 ± 1.49 0.30 ± 0.77
All 1.72 ± 1.35 1.83 ± 1.64 0.11 ± 0.89 B
(n = 21) (n = 20) (n = 20)
TNFα, pg/mL NP 2.93 ± 1.47 3.37 ± 1.31 1.06 ± 1.49
HP 2.97 ± 1.06 4.52 ± 2.11 0.65 ± 1.99
All 2.95 ± 1.24 4.00 ± 1.84 0.84 ± 1.74
(n = 19) (n = 19) (n = 19)
IL-6, pg/mL NP 3.55 ± 2.01 4.04 ± 2.50 1.04 ± 2.82
HP 2.62 ± 1.04 3.36 ± 1.68 0.75 ± 1.56
All 3.06 ± 1.60 3.38 ± 2.07 0.89 ± 2.20
(n = 20) (n = 20) (n = 20)
MCP-1, pg/mL NP 154.99 ± 42.42 175.45 ± 28.92 20.11 ± 45.26
HP 164.22 ± 36.47 167.79 ± 49.30 3.57 ± 27.40
All 160.07 ± 38.47 171.24 ± 40.58 11.44 ± 36.99 B
(n = 19) (n = 20) (n = 19)
Adiponectin, µg/mL NP 9.48 ± 2.39 8.07 ± 3.44 −0.92 ± 3.20
HP 11.76 ± 4.31 11.37 ± 5.63 −0.76 ± 4.62
All 10.69 ± 9.72 9.72 ± 4.85 −0.83 ± 3.94
1 Mean ± SD; Repeated measures ANCOVA controlling for sex: Time Effect (B p values < 0.05). HP, High protein;
HsCRP, High-sensitivity C-reactive protein; IL-6, Interleukin 6; MCP-1, Monocyte chemoattractant protein 1; NP,
Normal protein; TNFα, Tumor necrosis factor alpha.
4. Discussion
Contrary to the hypothesis, a 12-week HP diet with whole eggs did not improve muscle
composition, cardiometabolic health, or systemic inflammation in older adults with overweight
and obesity. In the absence of ≥10% weight loss or exercise training, diet-induced changes in
muscle composition (e.g., IMAT)—the primary outcome of interest—have rarely been addressed
in the literature. Research showing that increased total protein intake improves whole body
composition [35,36] and decreases elevated serum concentrations of numerous “IMAT contributors”
including glucose [37], free fatty acid, chylomicron, triglyceride [40,41], and pro-inflammatory
cytokines [38,39] provided scientific foundations for this study. Specifically, it was hypothesized
that increased total protein intake would improve muscle composition in older adults, a population
prone to IMAT accumulation [4] and muscle loss [52].
Changes in muscle composition were minimal over the 12-week intervention, showing no effect
of dietary protein on muscle composition in older adults. Though a decrease in calf subcutaneous fat to
muscle volume ratio was observed with the HP diet (p = 0.031), this alteration in fat to muscle volume
ratio is likely a result of a decrease in subcutaneous fat (p = 0.160) versus a change in IMAT (p = 0.780)
or muscle volume (p = 0.795) by the HP diet. There is a paucity of data on the effects of dietary protein,
within the context of a diet-only intervention (e.g. weight maintenance or diet-induced modest weight
loss), on muscle composition in older adults with overweight or obesity. Protein supplementation
(10 g/day) was associated with increased thigh muscle cross-sectional area (MSCA) in bedridden,
frail older adults (>70 years), whereas the current study population represents the average US older
adult who is still active, independent, and not severely protein-malnourished [53]. Therefore, current
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results suggest that higher dietary protein intake for 12 weeks does not influence muscle composition
in healthy older adults with overweight or obesity.
The 12-week dietary intervention did, however, alter the participants’ normal dietary habits
and change body composition. Independent of diet, biological sex, and despite increases in the
participant’s non-protein energy intake to maintain body weight, decreases in waist circumference,
total body mass, total fat mass, and total lean mass were observed over time. Such modest weight loss
often occurs following prescribed, fixed meal diets [54,55]. While in general, weight loss is associated
with improvements in health [56], the current study’s 3% decrease in body mass (−3.00 ± 2.43 kg)
did not affect the majority of study outcomes. Protein intake did, however, augment changes in
body composition following modest weight loss, where the HP diet prevented the loss of lean
mass observed with the NP diet over the 12-week intervention. This attenuation of lean mass
following modest weight loss is consistent with the literature and showcases dietary protein’s ability
to preferentially decrease fat mass over lean mass. A recent systematic review and meta-analysis
of 24 randomized controlled trials supports this claim. In accordance with PRISMA guidelines and
following the accumulation over 1500 articles from 4 different databases, meta-analyses revealed that
higher protein diets (> 1.0 g protein kg−1 d−1) attenuated more lean mass (+0.83 kg) and reduced
more fat mass (−0.53 kg) in older adults (>50 years, N = 242) in comparison to normal protein diets
(< 1.0 g protein kg−1 d−1) [57]. The current study further supports this effect of dietary protein to retain
lean mass during modest weight loss in older adults. The preservation of lean mass is essential for
health aging, as age-related decreases in lean mass are associated with impairments in mobility [25,58],
decreased independence [59], and an increased risk of all-cause mortality [60]. Collectively, a higher
protein diet can help maintain lean mass in older adults with overweight or obesity following modest
weight loss and increasing whole egg consumption provides a viable whole foods approach to increase
total protein intake.
Contrary to the hypothesis, only the NP diet influenced cardiometabolic health, decreasing
LDL concentration over the 12-week intervention. Consuming an egg-free NP diet for 12 weeks
decreased LDL concentration (−0.3 ± 0.3 mmol/L) in older adults with overweight and obesity, while
the HP diet, where at least 3 whole eggs were consumed per day, did not influence any marker of
cardiometabolic health. Though contrary to our hypothesis, these results are consistent with recent
findings [61–63] and show that consuming whole eggs does not influence total cholesterol, LDL
concentrations [62], endothelial function, blood pressure [61], nor atherosclerosis [63] in at risk adults
with overweight and obesity. Furthermore, whether the observed decrease in LDL concentrations
with the NP diet equates to improvements in cardiovascular health, particularly in individuals at
intermediate cardiovascular risk like the current study participants [64], has come under question in
recent years [65]. Despite statins proving effective in lowering LDL concentrations, many patients
continue to have clinical events following its reduction [66]. Therefore, recent recommendations
suggest lipoprotein ratios or “atherogenic indices” have a greater predictive capacity for cardiovascular
events in comparison to a single lipoprotein [67]. Thus, caution is given in the interpretation of the
study’s lipoprotein results as the total cholesterol to HDL ratio did not change in both diets over
the 12-weeks.
The current study extends literary knowledge by investigating the influence of diet composition
on changes in IMAT; assessing whether a diet-induced, whole-foods approach could decrease IMAT
without extensive weight loss or exercise training. Strengths of this study include the use of MRI
modality to assess medial thigh and calf muscle composition, DXA to assess changes in whole-body
composition, and the measurement of both cardiometabolic and inflammatory outcomes. There were
some limitations to the current study. Involuntary participant movement during the baseline and
post-intervention MRI data acquisition reduced thigh (n = 17) and calf (n = 15) MRI sample sizes
allotted for muscle composition analysis. Involuntary participant movement or muscle spasms
during MRI data acquisition is often the result of peripheral neuromuscular simulation as oscillating
magnetic field gradients can stimulate the peripheral nervous system and cause involuntary muscle
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spasms in healthy adults [68,69]. Therefore, if involuntary movement persists following additional
attempts, researchers should determine the appropriate imaging correction techniques to remove
motion artifacts [70,71]. Some may also consider the study’s modest weight loss (−3.3%) as a limitation,
potentially confounding results. However, considering weight-loss induced decreases in the primary
outcome interest (IMAT) seems to require at least a 10% decrease in body mass [29–33] and the vast
majority of secondary outcomes were unaffected by a similar amount of weight loss in both groups,
the study’s modest weight loss is unlikely to have influenced final interpretation. Post hoc power
calculations indicated that the variability in changes in IMAT following the HP and NP diets were
greater than anticipated, which may have limited the ability to detect diet-induced changes in IMAT
with the current sample size. However, the current study is among the first to study diet-induced
changes in IMAT, and currently the only study to investigate the effects of dietary protein on IMAT
without exercise training or ≥10% weight loss. Thus, the current study provides valuable results for
future investigators when making statistical power calculations.
5. Conclusions
For older adults with overweight and obesity, consumption of a high-protein diet with whole
eggs for 12 weeks promotes the retention of lean mass following modest weight loss. However,
increasing total protein intake and consuming three whole eggs per day does not provide an effective
dietary strategy to positively influence skeletal muscle composition, including IMAT, or indices of
cardiometabolic health and systemic inflammation, in comparison to a normal protein diet void of eggs.
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